Prognostic Value of the Vascular Lake Phenomenon in Large Hepatocellular Carcinoma Following Conventional TACE: A Retrospective Study.

Rationale And Objectives: The study aimed to evaluate risk factors related to the vascular lake phenomenon (VLP) and its impact on prognosis in patients with large hepatocellular carcinoma (HCC) (≥5 cm) undergoing Conventional transarterial chemoembolization (cTACE).

Patients And Methods: This study included 149 patients with large HCC who initially underwent cTACE from July 2021 to July 2023. The univariate and multivariate analyses were conducted to find risk factors related to VLP.

A sub-cluster of cancer cells indicates poor prognosis in advanced hepatocellular carcinoma.

Background: For patients with advanced hepatocellular carcinoma (HCC), it is emergent to focus on elucidating different classifications of intratumoral heterogeneity and understanding the mechanisms of treatment resistance to improve prognosis. This study aims to classify the sub-clusters of cancer cells in patients diagnosed with advanced HCC, and identify the genes, pathways and microenvironment associated with prognosis.

Methods: Single-cell transcriptomic profiling were conducted on advanced HCC samples.

PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal disease with limited effective treatment especially after first-line chemotherapy. The human epidermal growth factor receptor 2 (HER-2) immunohistochemistry (IHC) positive is associated with more aggressive clinical behavior and shorter overall survival in PDAC.

Case Summary: We present a case of multiple metastatic PDAC with IHC mismatch repair proficient but HER-2 IHC weakly positive at diagnosis that didn't have tumor regression after first-line nab-paclitaxel plus gemcitabine and PD-1 inhibitor treatment.

Biodistribution and preparation of technetium-99m-labeled D-D₃ monoclonal antibody against pro-gastrin-releasing peptide (₃₁₋₉₈) in mice.

Background: We previously reported that iodine-131((131)I)-labeled anti-pro-gastrin-releasing peptide (ProGRP(31-98)) monoclonal antibody D-D3 could selectively accumulate in the tumor sites of nude mice bearing small cell lung cancer (SCLC) xenografts. However, (131)I-D-D3 was cleared slowly from the body, and the best radioimmunoimaging time for SCLC was 72 - 96 hours after injection. The aims of this study were to radiolabel anti-ProGRP(31-98) D-D3 monoclonal antibody with technetium-99m ((99m)Tc) and to investigate the biodistribution of this antibody in healthy ICR mice.

[Values of (99m)TcO(-)(4)thyroid imaging plus ultrasonography in the differential diagnoses of thyroid nodules].

Objective: To evaluate the diagnostic values of (99m)TcO(-)(4) thyroid imaging plus ultrasonography in the differentiation of benign and malignant thyroid nodules.

Methods: (99m)TcO(-)(4) thyroid imaging and ultrasonography were performed for 114 patients with 125 thyroid nodules. And the examination results were compared with the post-operative pathological findings.